[1]
|
Song P, Liu Y, Yu X, et al. Prevalence of epilepsy in China between 1990 and 2015: A systematic review and meta-analysis[J]. J Glob Health, 2017, 7: 020706. doi: 10.7189/jogh.07.020706 |
[2]
|
Kalilani L, Sun X, Pelgrims B, et al. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis[J]. Epilepsia, 2018, 59: 2179-2193. doi: 10.1111/epi.14596 |
[3]
|
Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies[J]. Epilepsia, 2010, 51: 1069-1077. |
[4]
|
中国抗癫痫协会. 临床诊疗指南: 癫痫病分册[M]. 北京: 人民卫生出版社, 2015. |
[5]
|
Ng YT, Collins SD. Clobazam[J]. Neurotherapeutics, 2007, 4: 138-144. doi: 10.1016/j.nurt.2006.11.002 |
[6]
|
Nakajima H. A pharmacological profile of clobazam (Mystan), a new antiepileptic drug[J]. Nihon Yakurigaku Zasshi, 2001, 118: 117-122. doi: 10.1254/fpj.118.117 |
[7]
|
Humayun MJ, Samanta D, Carson RP. Clobazam[M]. StatPearls. Treasure Island (FL): StatPearls Publishing, 2022. |
[8]
|
FDA Approves Onfi. FDA approves onfi for seizures associated with lennox-gastaut syndrome[EB/OL]. (2022-01-02)[2022-08-11]. https://www.drugs.com/newdrugs/fda-approves-onfi-seizuresassociated-lennox-gastaut-syndrome-2921.html. |
[9]
|
Scottish Intercollegiate Guidelines Network. Epilepsies in children and young people: investigative procedures and managemen[EB/OL]. (2021-05)[2022-08-11]. https://www.sign.ac.uk/our-guidelines/epilepsies-in-children-and-young-people-investigative-procedures-and-manage-ment/. |
[10]
|
Joshi C, Nickels K, Demarest S, et al. Results of an international Delphi consensus in epilepsy with myoclonic atonic seizures/ Doose syndrome[J]. Seizure, 2021, 85: 12-18. doi: 10.1016/j.seizure.2020.11.017 |
[11]
|
Montouris G, Aboumatar S, Burdette D, et al. Expert opinion: Proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients[J]. Epilepsy Behav, 2020, 110: 107146. doi: 10.1016/j.yebeh.2020.107146 |
[12]
|
Wirrell EC, Laux L, Franz DN, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study[J]. Epilepsia, 2013, 54: 1595-1604. doi: 10.1111/epi.12303 |
[13]
|
Dressler A, Trimmel-Schwahofer P, Reithofer E, et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome-Comparison with various standard antiepileptic drug regimen[J]. Epilepsy Res, 2015, 109: 81-89. doi: 10.1016/j.eplepsyres.2014.10.014 |
[14]
|
Trivisano M, Striano P, Sartorelli J, et al. CHD2 mutations are a rare cause of generalized epilepsy with myoclonic-atonic seizures[J]. Epilepsy Behav, 2015, 51: 53-56. doi: 10.1016/j.yebeh.2015.06.029 |
[15]
|
Vlaskamp DR, Rump P, Callenbach PM, et al. Haploinsufficiency of the STX1B gene is associated with myoclonic astatic epilepsy[J]. Eur J Paediatr Neurol, 2016, 20: 489-492. doi: 10.1016/j.ejpn.2015.12.014 |
[16]
|
Song L, Liu F, Liu Y, et al. Clonazepam add-on therapy for drug-resistant epilepsy[J]. Cochrane Database Syst Rev, 2020, 4: Cd012253. |
[17]
|
国家药品监督管理局. 氯巴占临时进口工作方案[EB/OL]. (2022-06-29)[2022-08-11]. http://www.nhc.gov.cn/yaozs/s7653/202206/be5e83d15642445f89685af454e1557a.shtml. |
[18]
|
Centre for Evidence-Based Medicine. Oxford Center for Evidence-Based Medicine: Levels of Evidence(March 2009)[EB/OL]. (2009-03)[2022-08-11]. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009. |
[19]
|
翟菲菲, 卢强. 氯巴占在癫痫治疗中的研究进展[J]. 癫痫杂志, 2022, 8: 133-137. https://www.cnki.com.cn/Article/CJFDTOTAL-DXZA202202006.htm |
[20]
|
Sankar R. GABA(A) receptor physiology and its relationship to the mechanism of action of the 1, 5-benzodiazepine clobazam[J]. CNS Drugs, 2012, 26: 229-244. doi: 10.2165/11599020-000000000-00000 |
[21]
|
Strzelczyk A, Schubert-Bast S. Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies[J]. CNS Drugs, 2021, 35: 61-83. doi: 10.1007/s40263-020-00784-8 |
[22]
|
Trevathan E, Murphy CC, Yeargin-Allsopp M. Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children[J]. Epilepsia, 1997, 38: 1283-1288. doi: 10.1111/j.1528-1157.1997.tb00065.x |
[23]
|
European Commission. Rare Disease Registries in Europe. September 2020[EB/OL]. (2020-09)[2022-08-11]. https://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf. |
[24]
|
National Organization for Rare Disorders. Rare Disease Database[EB/OL]. [2022-08-11]. https://rarediseases.org/for-patients-and-families/information-resources/rare-disease-information/. |
[25]
|
Ostendorf AP, Ng YT. Treatment-resistant Lennox-Gastaut syndrome: therapeutic trends, challenges and future directions[J]. Neuropsychiatr Dis Treat, 2017, 13: 1131-1140. doi: 10.2147/NDT.S115996 |
[26]
|
Cross JH, Auvin S, Falip M, et al. Expert Opinion on the Management of Lennox-Gastaut Syndrome: Treatment Algorithms and Practical Considerations[J]. Front Neurol, 2017, 8: 505. doi: 10.3389/fneur.2017.00505 |
[27]
|
National Institute for Health and Care Excellence. Clinical Guidelines. Epilepsies: diagnosis and management[M]. London: National Institute for Health and Care Excellence, 2021. |
[28]
|
季涛云, 姜玉武, 蒋莉, 等. Lennox-Gastaut综合征诊断治疗的中国专家共识[J]. 癫痫杂志, 2022, 8: 187-195. https://www.cnki.com.cn/Article/CJFDTOTAL-DXZA202203014.htm |
[29]
|
Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome[J]. Epilepsia, 2009, 50: 1158-1166. doi: 10.1111/j.1528-1167.2008.01935.x |
[30]
|
Ng YT, Conry JA, Drummond R, et al. Randomized, phase Ⅲ study results of clobazam in Lennox-Gastaut syndrome[J]. Neurology, 2011, 77: 1473-1481. doi: 10.1212/WNL.0b013e318232de76 |
[31]
|
Ng YT, Conry J, Paolicchi J, et al. Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study[J]. Epilepsy Behav, 2012, 25: 687-694. doi: 10.1016/j.yebeh.2012.09.039 |
[32]
|
Conry JA, Ng YT, Kernitsky L, et al. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years[J]. Epilepsia, 2014, 55: 558-567. doi: 10.1111/epi.12561 |
[33]
|
Cramer JA, Sapin C, François C. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome[J]. Acta Neurol Scand, 2013, 128: 91-99. doi: 10.1111/ane.12086 |
[34]
|
Devi N, Madaan P, Ameen R, et al. Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: A network meta-analysis[J]. Seizure, 2022, 99: 164-175. doi: 10.1016/j.seizure.2022.04.004 |
[35]
|
Zhang L, Wang J, Wang C. Efficacy and safety of antisei-zure medication for Lennox-Gastaut syndrome: a systematic review and network meta-analysis[J]. Dev Med Child Neurol, 2022, 64: 305-313. doi: 10.1111/dmcn.15072 |
[36]
|
Engel J Jr, International League Against Epilepsy. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology[J]. Epilepsia, 2001, 42: 796-803. doi: 10.1046/j.1528-1157.2001.10401.x |
[37]
|
Sun H, Zhang Y, Liu X, et al. Analysis of SCN1A mutation and parental origin in patients with Dravet syndrome[J]. J Hum Genet, 2010, 55: 421-427. doi: 10.1038/jhg.2010.39 |
[38]
|
Connolly MB. Dravet Syndrome: Diagnosis and Long-Term Course[J]. Can J Neurol Sci, 2016, 43: S3-S8. |
[39]
|
刘家雯, 操德智. Dravet综合征临床治疗新进展[J]. 中华实用儿科临床杂志, 2018, 33: 1913-1917. doi: 10.3760/cma.j.issn.2095-428X.2018.24.020 |
[40]
|
Lagae L. Dravet syndrome[J]. Curr Opin Neurol, 2021, 34: 213-218. doi: 10.1097/WCO.0000000000000902 |
[41]
|
Tanabe T, Awaya Y, Matsuishi T, et al. Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI, Dravet syndrome)--a nationwide questionnaire survey in Japan[J]. Brain Dev, 2008, 30: 629-635. doi: 10.1016/j.braindev.2008.03.002 |
[42]
|
Wirrell EC, Laux L, Donner E, et al. Optimizing the Diagnosis and Management of Dravet Syndrome: Recommenda-tions From a North American Consensus Panel[J]. Pediatric Neurol, 2017, 68: 18-34. e3. doi: 10.1016/j.pediatrneurol.2017.01.025 |
[43]
|
Cross JH, Caraballo RH, Nabbout R, et al. Dravet syndrome: Treatment options and management of prolonged seizures[J]. Epilepsia, 2019, 60: S39-S48. |
[44]
|
Brigo F, Igwe SC, Bragazzi NL. Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy[J]. Cochrane Database Syst Rev, 2017, 5: CD010483. |
[45]
|
Doose H, Gerken H, Leonhardt R, et al. Centrencephalic myoclonic-astatic petit mal. Clinical and genetic investigation[J]. Neuropadiatrie, 1970, 2: 59-78. doi: 10.1055/s-0028-1091841 |
[46]
|
Kelley SA, Kossoff EH. Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress[J]. Dev Med Child Neurol, 2010, 52: 988-993. doi: 10.1111/j.1469-8749.2010.03744.x |
[47]
|
陈娇阳, 张月华. 癫痫伴肌阵挛-失张力发作的分子遗传学研究进展[J]. 中华儿科杂志, 2019, 57: 384-387. doi: 10.3760/cma.j.issn.0578-1310.2019.05.015 |
[48]
|
Nickels K, Kossoff EH, Eschbach K, et al. Epilepsy with myoclonic-atonic seizures (Doose syndrome): Clarification of diagnosis and treatment options through a large retrospective multicenter cohort[J]. Epilepsia, 2021, 62: 120-127. doi: 10.1111/epi.16752 |
[49]
|
Kilaru S, Bergqvist AGC. Current treatment of myoclonic astatic epilepsy: clinical experience at the Children's Hospital of Philadelphia[J]. Epilepsia, 2007, 48: 1703-1707. doi: 10.1111/j.1528-1167.2007.01186.x |
[50]
|
Stephani U. The natural history of myoclonic astatic epilepsy (Doose syndrome) and Lennox-Gastaut syndrome[J]. Epilepsia, 2006, 47: 53-55. doi: 10.1111/j.1528-1167.2006.00690.x |
[51]
|
McTague A, Cross JH. Treatment of epileptic encephalopathies[J]. CNS Drugs, 2013, 27: 175-184. doi: 10.1007/s40263-013-0041-6 |
[52]
|
邓劼, 张月华, 杨志仙, 等. 肌阵挛失张力癫痫48例治疗及预后随访[J]. 中国实用儿科杂志, 2012, 27: 57-61. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSEK201201019.htm |
[53]
|
Nickels K, Thibert R, Rau S, et al. How do we diagnose and treat epilepsy with myoclonic-atonic seizures (Doose syndrome)? Results of the Pediatric Epilepsy Research Consortium survey[J]. Epilepsy Res, 2018, 144: 14-19. doi: 10.1016/j.eplepsyres.2018.04.010 |
[54]
|
Ito S, Nagumo K, Nishikawa A, et al. Low-dose phenobarbital for epilepsy with myoclonic absences: A case report[J]. Brain Dev, 2021, 43: 666-668. doi: 10.1016/j.braindev.2020.12.018 |
[55]
|
Wallace A, Wirrell E, Kenney-Jung DL. Pharmacotherapy for Dravet Syndrome[J]. Paediatric Drugs, 2016, 18: 197-208. doi: 10.1007/s40272-016-0171-7 |
[56]
|
Anon. Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Canadian Cloba-zam Cooperative Group[J]. Epilepsia, 1991, 32: 407-416. doi: 10.1111/j.1528-1157.1991.tb04670.x |
[57]
|
Contin M, Sangiorgi S, Riva R, et al. Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam[J]. Ther Drug Monit, 2002, 24: 737-741. doi: 10.1097/00007691-200212000-00009 |
[58]
|
Walzer M, Bekersky I, Blum RA, et al. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes[J]. Pharmacotherapy, 2012, 32: 340-353. doi: 10.1002/j.1875-9114.2012.01028.x |
[59]
|
Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017[J]. Pharmacopsychiatry, 2018, 51: 9-62. doi: 10.1055/s-0043-116492 |
[60]
|
Rupp W, Badian M, Christ O, et al. Pharmacokinetics of single and multiple doses of clobazam in humans[J]. Br J Clin Pharmacol, 1979, 7: 51S-57S. doi: 10.1111/j.1365-2125.1979.tb04665.x |
[61]
|
Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies[J]. Epilepsia, 2008, 49: 1239-1276. doi: 10.1111/j.1528-1167.2008.01561.x |
[62]
|
Guberman A, Couture M, Blaschuk K, et al. Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations[J]. Can J Neurol Sci, 1990, 17: 311-316. doi: 10.1017/S031716710003064X |
[63]
|
Aylett SE, Cross H, Berry D. Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy[J]. Dev Med Child Neurol, 2006, 48: 612-615. doi: 10.1017/S0012162206001289 |
[64]
|
Montenegro MA, Arif H, Nahm EA, et al. Efficacy of clobazam as add-on therapy for refractory epilepsy: experience at a US epilepsy center[J]. Clin Neuropharmacol, 2008, 31: 333-338. doi: 10.1097/WNF.0b013e31815cd960 |
[65]
|
Naccarato M, Yoong D, Kovacs C, et al. A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy[J]. Antivir ther, 2012, 17: 589-592. doi: 10.3851/IMP1953 |
[66]
|
Parmeggiani A, Posar A, Sangiorgi S, et al. Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19[J]. Brain Dev, 2004, 26: 63-66. doi: 10.1016/S0387-7604(03)00074-3 |
[67]
|
Pok PR, Mauras M, De Saint Léger MN, et al. Blood concentrations of clobazam and norclobazam in a lethal case involving clobazam, meprobamate and clorazepate[J]. Legal Med (Tokyo), 2010, 12: 300-304. doi: 10.1016/j.legalmed.2010.08.002 |
[68]
|
Proença P, Teixeira H, Pinheiro J, et al. Forensic intoxication with clobazam: HPLC/DAD/MSD analysis[J]. Forensic Sci Int, 2004, 143: 205-209. doi: 10.1016/j.forsciint.2004.03.029 |
[69]
|
Dean L. Clobazam Therapy and CYP2C19 Genotype[M]. US: National Center for Biotechnology Information, 2012. |
[70]
|
Johannessen Landmark C, Heger K, Lund C, et al. Pharmacokinetic Variability During Long-Term Therapeutic Drug Monitoring of Valproate, Clobazam, and Levetiracetam in Patients With Dravet Syndrome[J]. Ther Drug Monit, 2020, 42: 744-753. doi: 10.1097/FTD.0000000000000781 |
[71]
|
Burns ML, Baftiu A, Opdal MS, et al. Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability[J]. Ther Drug Monit, 2016, 38: 350-357. doi: 10.1097/FTD.0000000000000272 |
[72]
|
De Leon J, Spina E, Diaz FJ. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies[J]. Thera Drug Monit, 2013, 35: 30-47. doi: 10.1097/FTD.0b013e31827ada88 |
[73]
|
Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics[J]. Pharmacol Res, 2016, 106: 72-86. doi: 10.1016/j.phrs.2016.02.014 |
[74]
|
Anon. Thioridazine[J]. Tuberculosis (Edinb), 2008, 88: 164-167. doi: 10.1016/S1472-9792(08)70028-3 |
[75]
|
Pasupuleti B, Gone V, Baddam R, et al. Clinical Impact of Co-medication of Levetiracetam and Clobazam with Proton Pump Inhibitors: A Drug Interaction Study[J]. Curr Drug Metab, 2020, 21: 126-131. doi: 10.2174/1389200221666200218121050 |
[76]
|
Monjanel-Mouterde S, Antoni M, Bun H, et al. Pharmacokinetics of a single oral dose of clobazam in patients with liver disease[J]. Pharmacol Toxicol, 1994, 74: 345-350. doi: 10.1111/j.1600-0773.1994.tb01371.x |
[77]
|
Tolbert D, Bekersky I, Chu HM, et al. An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokine-tics[J]. J Clin Pharmacol, 2016, 56: 213-222. doi: 10.1002/jcph.586 |
[78]
|
Kamitaki BK, Minacapelli CD, Zhang P, et al. Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS)[J]. Epilepsy Behav, 2021, 117: 107832. doi: 10.1016/j.yebeh.2021.107832 |
[79]
|
Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant[J]. Psychiatr Serv, 2002, 53: 39-49. doi: 10.1176/appi.ps.53.1.39 |
[80]
|
Noh Y, Lee H, Choi A, et al. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: A population-based cohort study in South Korea[J]. PLoS Med, 2022, 19: e1003945. doi: 10.1371/journal.pmed.1003945 |
[81]
|
Suresh L, Radfar L. Pregnancy and lactation[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2004, 97: 672-682. doi: 10.1016/j.tripleo.2004.02.002 |
[82]
|
Greenblatt DJ, Divoll M, Puri SK, et al. Reduced single-dose clearance of clobazam in elderly men predicts increased multiple-dose accumulation[J]. Clin Pharmacokinet, 1983, 8: 83-94. doi: 10.2165/00003088-198308010-00005 |
[83]
|
Greenblatt DJ, Divoll M, Puri SK, et al. Clobazam kinetics in the elderly[J]. Br J Clin Pharmacol, 1981, 12: 631-636. doi: 10.1111/j.1365-2125.1981.tb01281.x |
[84]
|
Tolbert D, Chu HM, Ette EI. Pharmacometrics of clobazam in pediatrics: Prediction of effective clobazam doses for Dravet syndrome[J]. Epilepsy Res, 2019, 157: 106182. doi: 10.1016/j.eplepsyres.2019.106182 |
[85]
|
Hahn J, Lee H, Kang HC, et al. Clobazam as an adjunctive treatment for infantile spasms[J]. Epilepsy Behav, 2019, 95: 161-165. doi: 10.1016/j.yebeh.2019.03.040 |
[86]
|
Mahmoud SH, Rans C. Systematic review of clobazam use in patients with status epilepticus[J]. Epilepsia Open, 2018, 3: 323-330. doi: 10.1002/epi4.12230 |
[87]
|
Redondo P, Vicente J, España A, et al. Photo-induced toxic epidermal necrolysis caused by clobazam[J]. Br J Dermatol, 1996, 135: 999-1002. doi: 10.1046/j.1365-2133.1996.d01-1111.x |
[88]
|
Yapici AK, Fidanci MK, Kilic S, et al. Stevens-Johnson Syndrome triggered by a combination of clobazam, lamotrig-ine and valproic acid in a 7-year-old child[J]. Ann Burns Fire Disasters, 2014, 27: 121-125. |
[89]
|
Caramaschi P, Biasi D, Carletto A, et al. Clobazam-induced systemic lupus erythematosus[J]. Clin Rheumatol, 1995, 14: 116. |
[90]
|
US. Food & Durg. FDA Drug Safety Communication: FDA warns of serious skin reactions with the anti-seizure drug Onfi (clobazam) and has approved label changes[EB/OL]. (2016-01-15)[2022-08-11]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-serious-skin-reactions-anti-seizure-drug-onfi-cloba-zam-and#:~:text=%5B12-32013%5D%20The%20U.S.%20Food%20and%20Drug%20Administration%20%28FDA%29,describe%20the%20risk%20of%20these%20serious%20skin%20reactions. |
[91]
|
Chen B, Choi H, Hirsch LJ, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy[J]. Epilepsy Behav, 2017, 76: 24-231. doi: 10.1016/j.yebeh.2017.08.039 |
[92]
|
Kalra V, Seth R, Mishra D, et al. Clobazam in refractory childhood epilepsy[J]. Indian J Pediatr, 2010, 77: 263-266. doi: 10.1007/s12098-010-0035-z |
[93]
|
Gedela S, Freedman DA, Gedela S, et al. Safety and Efficacy of Supratherapeutic Doses of Clobazam[J]. J Child Neurol, 2019, 34: 735-738. doi: 10.1177/0883073819856834 |
[94]
|
Schmidt D. Clobazam for treatment of intractable epilepsy: a critical assessment[J]. Epilepsia, 1994, 35: S92-S95. doi: 10.1111/j.1528-1157.1994.tb05979.x |